Welcome to our dedicated page for Aytu Biopharma news (Ticker: AYTU), a resource for investors and traders seeking the latest updates and insights on Aytu Biopharma stock.
Aytu BioPharma, Inc. (AYTU) is a Nasdaq-listed pharmaceutical company focused on advancing medicines for complex central nervous system diseases, with an emphasis on major depressive disorder (MDD) and attention deficit-hyperactivity disorder (ADHD). Its news flow reflects this focus, highlighting commercial progress, clinical positioning and corporate developments around its prescription portfolio.
A central theme in Aytu’s recent news is EXXUA (gepirone) extended-release tablets, a novel oral selective serotonin 5HT1a receptor agonist indicated for the treatment of MDD in adults. Company announcements have covered the commercial availability of EXXUA in the United States, its status as the first and only 5HT1a agonist approved by the U.S. Food and Drug Administration for MDD, and integration of EXXUA distribution into Aytu’s RxConnect patient access platform.
Investors following AYTU news will also see updates on the company’s ADHD Portfolio and Pediatric Portfolio performance, including revenue trends and commentary from management in quarterly operational and financial results. Aytu’s press releases discuss net revenue by portfolio, gross profit, adjusted EBITDA and investments related to the EXXUA launch.
In addition, Aytu regularly announces participation in investor conferences, healthcare summits and dedicated Investor Day events. These items often feature presentations by senior management and key opinion leaders in psychiatry, focusing on EXXUA’s clinical profile, market opportunity and the company’s broader CNS strategy. For investors and observers, the AYTU news page provides a centralized view of product launches, patent developments, financing updates and ongoing investor outreach activities.
Aytu BioPharma announced a record 5,186 prescriptions for Adzenys XR-ODT for the week ending November 18, 2022, marking a 9.9% increase over the prior 13-week period. This increase is attributed to strong sales force execution and effective use of the Aytu RxConnect patient support program. Adzenys XR-ODT, an FDA-approved bioequivalent to Adderall XR, remains available without disruption, providing an alternative amid ongoing supply issues affecting Adderall. The company ensures consistent production at its Texas facility.
Aytu BioPharma has received a 180-day extension from Nasdaq to comply with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The deadline is set for May 22, 2023. Aytu must keep its stock price above $1.00 for at least 10 consecutive business days to regain compliance. The company is considering options, including a reverse stock split, to achieve this. If compliance is not met, Aytu’s stock could be delisted, although it can appeal any such decision. Aytu's stock continues to trade on Nasdaq under the symbol AYTU.
Aytu BioPharma has been ranked 94th on the Deloitte Technology Fast 500 and 21st among life sciences companies for the second consecutive year. This recognition highlights the company's growth, driven by a 47% increase in net revenue to $96.7 million in fiscal 2022, with an impressive 87% growth in prescription products sales. Aytu recently reported positive adjusted EBITDA in its first quarter of fiscal 2023. CEO Josh Disbrow emphasized the team's efforts in achieving commercial success and positive cash flows.
Aytu BioPharma (NASDAQ:AYTU) announced the passing of co-founder and board member Michael Macaluso on November 16, 2022. CEO Josh Disbrow expressed condolences, highlighting Macaluso's significant contributions since the company's inception in 2015. Macaluso served as Chair of the Compensation Committee and was integral to Aytu's growth, drawing on his four-decade entrepreneurial career in the life sciences sector. His diverse background included leadership roles at Ampio Pharmaceuticals and Isolagen, reflecting his deep industry expertise.
Aytu BioPharma reported a record quarterly net revenue of $27.7 million for Q1 2023, a 26% increase from $21.9 million year-over-year. Revenue from the Rx segment rose 34% to $18.7 million, with ADHD products increasing by 24% and pediatric products by 73%. The company achieved a positive Adjusted EBITDA of $1.4 million compared to a loss of $4.2 million last year. Strategic leadership changes were made to enhance commercial operations. The indefinite suspension of R&D programs is projected to save over $20 million in future costs.
Aytu BioPharma (Nasdaq: AYTU) will announce its first quarter fiscal year 2023 financial results after the market closes on November 14, 2022. A conference call to discuss these results is scheduled for the same day at 4:30 pm ET. Investors can join the call by dialing (877) 545-0523 or (973) 528-0016, using access code 883834. The call will also be available via webcast, with an archive lasting 90 days. Aytu's product portfolio includes prescription drugs for ADHD and a variety of consumer health products.
Aytu BioPharma announced an amendment to its secured loan agreement with Avenue Venture Debt Fund, extending the interest-only period to January 2024. This amendment defers over $3 million in principal payments into 2024 and 2025, aiding cash conservation. The loan matures in January 2025, with additional interest-only extensions possible upon achieving certain milestones. The reset of the warrant exercise price to $0.43 is part of this agreement, reflecting the company's latest equity financing. CEO Josh Disbrow emphasized this move supports their operational goals.
Aytu BioPharma has announced a strategic shift focusing on commercial operations, leading to the indefinite suspension of clinical development programs including AR101/enzastaurin for Vascular Ehlers-Danlos Syndrome (VEDS). This decision aims to save over $20 million in future study costs and is expected to enable the company to achieve positive quarterly Adjusted EBITDA in the first half of 2023. In the last fiscal year, Aytu's commercial operations generated $96.7 million in revenue, with a slight negative Adjusted EBITDA of $(961,000) for the quarter ending June 30, 2022.
Aytu BioPharma announces the uninterrupted supply of Adzenys XR-ODT, FDA-approved as a bioequivalent to Adderall XR, amidst reported disruptions affecting generic ADHD medications. Adzenys XR-ODT is an extended-release, orally disintegrating tablet for treating ADHD in patients aged six and older, with a twelve-hour duration of action. The company has ensured consistent production at its Texas facility, offering various strengths. Patients are encouraged to consult their physicians regarding medication options due to ongoing supply issues with other ADHD treatments.
Aytu BioPharma reported record fourth quarter net revenue of $27.4 million, a 17% increase from last year, driven by a 28% growth in the Prescription segment. Full year revenue rose 47% to $96.7 million, with Prescription products achieving 87% growth at $61.1 million. Adjusted EBITDA for Prescription was $1.1 million, contrasting with $(5.5) million last year. Despite a 2% decline in Consumer Health revenue due to supply chain issues, the overall Gross Profit margin improved to 54%. Net loss for the quarter was $(17.7) million, improving from $(19.0) million year-over-year.